Dr. Marcela Viviana Karpuj
מחלקה:
Biotechnology Engineering
תפקיד נוכחי:
Senior Lecturer
Research Interests
- 1. Neurodegenerative (NDS) and infectious diseases
- 2. Personalized Medicine
- 3. Drug delivery (nanoparticles and BBB)
- 4. The Genetic, environmental and character attributes and their influence on NDS
- 5. Membrane protein in health and disease
- 6. Anti-cancer drug screening utilizing a novel loss-of-function technology
Courses
- 1. Biotechnology engineering
- 2. Scientific writing
- 3. Molecular Biology (laboratory)
- 4. Biochemistry I (Course and Laboratory)
- 5. Advanced genetic engineering (B.Sc)
Refereed Papers
1. Takai, K., Drain, A. P., Lawson, D. A., Littlepage, L. E., Karpuj, M., Kessenbrock, K., Le, A., Inoue, K., Weaver, V. M., Werb, Z. (2018). Discoidin domain receptor 1 (DDR1) ablation promotes tissue fibrosis and hypoxia to induce aggressive basal-like breast cancers.
Genes Dev. 32, 244-257.
2. Broce, S., Hensley, L., Sato, T., Lehrer-Graiwer, J., Essrich, C., Edwards, K.J., Pajda, J., Davis, C.J., Bhadresh, R., Hurt, C.R., and Karpuj, M. (2016). Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals. Biology Direct. 11, 25.
3. Van Strien, M.E., de Vries, H.E., Chrobok, N.L., Bol, J.G.J.M., Breve, J.J.P., van der Pol, S.M.P., Kooij, G., van Buul, J.D., Karpuj, M., Steinman, L., et al. (2015). Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration. Brain Behaviour Immunology. 50, 141–154.
4. Nardone, S., Sams, D.S., Reuveni, E., Getselter, D., Oron, O., Karpuj, M., and Elliott, E. (2014). DNA methylation analysis of the autistic brain reveals multiple dysregulated biological pathways. Translational Psychiatry 4, e433.
5. Ben-Gedalya, T., Lyakhovetsky, R., Yedidia, Y., Bejerano-Sagie, M., Kogan, N.M., Karpuj, M.V., Kaganovich, D., and Cohen, E. (2011). Cyclosporin-A-induced prion protein aggresomes are dynamic quality-control cellular compartments. Journal of Cell Science. 124, 1891–1902.
6. Karpuj, M.V., Gelibter-Niv, S., Tiran, A., Rambold, A., Tatzelt, J., Nunziante, M., and Schatzl, H.M. (2011). Conditional modulation of membrane protein expression in cultured cells mediated by prion protein recognition of short phosphorothioate oligodeoxynucleotides. Journal of Biological Chemistry 286, 6911–6917.
7. Karpuj, M., Smith, D., Kelley-Clarke, B., Stossel, A., Honko, A., Broce, S., Van Loan, N., Harrell, E., Kelleher, C., Lingappa, J.R., et al. (2010). Small Molecule Therapeutics of Viruses of Families Bunyaviridae and Arenaviridae. Antiviral Ressearch. 86, A58–A58.
8. Karpuj, M.V., Giles, K., Gelibter-Niv, S., Scott, M.R., Lingappa, V.R., Szoka, F.C., Peretz, D., Denetclaw, W., and Prusiner, S.B. (2007). Phosphorothioate oligonucleotides reduce PrPSc levels and prion infectivity in cultured cells. Journal of Molecular Medicine. 13, 190–198.
9. Karpuj, M., and Steinman, L. (2004). The multifaceted role of transglutaminase in neurodegeneration: Review article. Amino Acids 26, 373–379.
10. Karpuj, M.V., Becher, M.W., and Steinman, L. (2002). Evidence for a role for transglutaminase in Huntington’s disease and the potential therapeutic implications. Neurochemistry International. 40, 31–36.
11. Karpuj, M.V., Becher, M.W., Springer, J.E., Chabas, D., Pedotti, R., Youssef, S., Mitchell, D., and Steinman, L. (2002). Prolonged survival and decreased abnormal movements in transgenic model of Huntington disease, with administration of the transglutaminase inhibitor cystamine . Nature Medicine. 8, 303–303.
12. Karpuj, M.V., Becher, M.W., and Steinman, L. (2002). Evidence for a role for transglutaminase in Huntington’s disease and the potential therapeutic implications. Neurochemistry International. 40, 31–36.
13. Pedotti, R., Mitchell, D., Wedemeyer, J., Karpuj, M., Chabas, D., Tsai, M., Galli, S.J., and Steinman, L. (2001). An unexpected version of horror autotoxicus. Anaphylactic shock to a self-peptide. Federation of American Society for Experimental Bioalogy journal. 15, A1218–A1218.
14. Pedotti, R., Mitchell, D., Wedemeyer, J., Karpuj, M., Chabas, D., Tsai, M., Galli, S.J., and Steinman, L. (2001). Allergy to self: An unexpected immune response in EAE. Neurology 56, A94–A94.
15. Chabas, D.E., Steinman, L., Rittling, S.R., Sobel, R., Lock, C., Mitchell, D., Pedotti, R., Karpuj, M., Heller, R., Oksenberg, J., et al. (2001). Elevated osteopontin transcripts in MS brain libraries and its role in the development of progressive versus relapsing autoimmune encephalomyelitis. Neurology 56, A467–A467.
16. Chabas, D., Baranzini, S.E., Mitchell, D., Bernard, C.C.A., Rittling, S.R., Denhardt, D.T., Sobel, R.A., Lock, C., Karpuj, M., Pedotti, R., et al. (2001). The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 294, 1731–1735.
17. Karpuj, M.V., Chan, P., Di Monte, D., Langston, J.W., and Steinman, L. (2000). Gene microarray analysis of Parkinson’s disease specimens. Neurology 54, A427–A427.
18. Karpuj, M.V., and Steinman, L. (2000). Transglutaminase aggregates Huntingtin into Non-Amyloidogenic Polymers and its enzymatic activity is increased in Huntington’s disease brain nuclei. Journal of Neurochemistry. 74, S96–S96.
19. Ruiz, P.J., Garren, H., Ruiz, I.U., Hirschberg, D.L., Nguyen, L.V.T., Karpuj, M.V., Cooper, M.T., Mitchell, D.J., Fathman, C.G., and Steinman, L. (1999). Suppressive immunization with DNA encoding a self-peptide prevents autoimmune disease: Modulation of T cell costimulation. Journal of Immunology. 162, 3336–3341.
20. Ruiz, P.J., Garren, H., Hirschberg, D.L., Langer-Gould, A.M., Levite, M., Karpuj, M.V., Southwood, S., Sette, A., Conlon, P., and Steinman, L. (1999). Microbial epitopes act as altered peptide ligands to prevent experimental autoimmune encephalomyelitis. Journal of Experimental Medicine. 189, 1275–1283.
21. Karpuj, M.V., Garren, H., Slunt, H., Price, D.L., Gusella, J., Becher, M.W., and Steinman, L. (1999). Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington’s disease brain nuclei. Proceedings National Academy of Science U. S. A. 96, 7388–7393.
22. Ruiz, P.J., Wolkowicz, R., Waisman, A., Hirschberg, D.L., Carmi, P., Erez, N., Garren, H., Herkel, J., Karpuj, M., Steinman, L., et al. (1998). Idiotypic immunization induces immunity to mutated p53 and tumor rejection. Nature Medicine. 4, 710–712.
23. Karpuj, M.V., Steinman, L., and Oksenberg, J.R. (1997). Multiple sclerosis: a polygenic disease involving epistatic interactions, germline rearrangements and environmental effects. Neurogenetics 1, 21–28.
24. Tal, M., Ammar, D., Karpuj, M., Krizhanovsky, V., Naim, M., and Thompson, D. (1995). Novel Putative Neuropeptide Receptor Expressed in Neural Tissue, Including Sensory Epithelia. Biochemicla Biophysical Research Communication. 209, 752–759.
Other Publications
C. Patents
1. Patent Application: US Number 09/719,770; Yeda Reference 9829; “The Involvement of Transglutaminase in Neurodegenerative Diseases”.
2. Pending Patent Application: US Number 20,110,311,533; Marcela Karpuj; “Regulation of Protein Level”.